Day 1Monday, 17 March 2025

Location: Coral 1

This session is an interactive workshop which aims to provide participants with practical tools, ideas and best practices to consider when creating and structuring your pitch presentations. It also dives into understanding how to enhance your professional behaviour and tap into your emotional intelligence when in pitching, partnering and negotiating situations, to lead to successful long-term partnerships.

Part 1 – Your presentation sets a precedent for partnership

• Influence or educate?
• Utilising Aristotle’s four rhetorical appeals
• Tuning in to others’ pains and gains

Part 2 - What’s your point?

• Preparing your most compelling message
• Less is more
• What do you want them to take away?

Part 3 – Packaging a winning presentation

• Opening for attention
• A powerful structure to reinforce your key messages
• Closing for impact

Location: Coral 3

As the biotech and pharma industries grapple with a dynamic global environment, deal-making remains a vital lever for growth and innovation. This session will address strategies for navigating the current financing environment, geopolitical tensions, and the opportunities expected to drive increased deal-making activity in 2025. Discover how collaboration and investment can propel the industry forward in the face of evolving challenges.

Location: Coral 2

The launch of Alys Pharmaceuticals with $100 million in financing by Medicxi marks a transformative milestone in the biotech landscape. Formed from the merger of six asset-centric companies, Alys represents a bold, R&D-driven approach to tackling significant unmet needs in immuno-dermatology. With a pipeline spanning cutting-edge modalities—from peptides to vectorized siRNA—Alys is set to deliver groundbreaking treatments for prevalent conditions like chronic urticaria, atopic dermatitis, vitiligo, and alopecia areata, as well as rare and underserved dermatological indications.

This fireside chat will explore the strategic vision and innovative framework that powered Alys' formation, shedding light on how startups and biotech companies can leverage similar models to accelerate their growth and impact. Leading KOL, Dr Brian Kim, will join Francesco De Rubertis to highlight the importance of following the science and listening to physicians to determine unmet medical needs. The session will highlight the critical opportunities available for advancing science, securing funding, and building sustainable pipelines. Attendees will gain actionable lessons on how to harness asset-centric strategies, multi-platform pipelines, and cutting-edge science to transform their therapeutic vision into reality.

Whether you're an early-stage innovator or an established biotech seeking inspiration, this discussion will offer invaluable guidance on scaling breakthroughs and driving the next generation of innovation in life sciences.

Location: Coral 2

Our Strategy
We're on course to transform the practice of medicine through breakthrough science and make a positive impact on our people and the communities we serve.

The Voices Behind Our Purpose
We chase the miracles of science to improve people's lives, and sometimes that means starting over with Plan B, Plan C, or even Plan Z. This film brings together the inner thoughts and ambitions of the people at Sanofi, who find inspiration from loved ones, motivation from families, and a united strength to push harder until we turn a corner.

Transforming The Practice of Medicine
Prioritization and focus are helping us unlock and maximize the potential of key medicines, vaccines, and self-care solutions for people, across our global business units: Specialty Care, Vaccines, General Medicines, and Consumer Healthcare.

We aim to become a leading company in immunology and positively impact millions of patients suffering from dermatological, respiratory, gastroenterological, and other immune-mediated diseases.

We earn every day our leadership in prevention by protecting half a billion people worldwide every year with our portfolio of vaccines and by leveraging our broad set of technology and manufacturing platforms, including in mRNA.

Advancing Breakthrough Science
We're strengthening our pipeline with a steady stream of potentially transformative therapies that could shift paradigms in treatment and prevention for people across the world.

We have a powerful toolbox of drug discovery platforms that allow us to break scientific ground in six therapeutic areas: Immunology and Inflammation, Oncology, Rare Diseases, Rare Blood Disorders, Neurology and Vaccines.

Driving Social Impact
The challenges facing society and the planet are becoming increasingly more complex. Shifting demographics, persistent inequalities in access to healthcare, and accelerating threats from climate change have motivated us to expand our commitments to society.

Location: Coral 2

Our purpose: We use the power of leading-edge science to save and improve lives around the world
For more than 130 years, we've brought hope to humanity through the development of important medicines and vaccines. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Location: Coral 2

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs.
The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.
As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology. Neuroscience is a future growth driver. In this area, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.
Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.9 billion in 2024.
Positioned as a Partner of choice:
- Private mid-size pharma company, ensuring continuity and long-term perspective in partnerships
- Global geographical footprint, with a presence in both established and emerging markets
- Science driven with strong R&D investment to build a high-quality and sustainable portfolio
- Fully integrated capabilities from research to commercialization
- Flexible and agile, we have over 60 strategic alliances with pharma companies, biotechs and academics worldwide to accelerate innovation.

Location: Coral 2

Almirall is a leading global biopharmaceutical company focused on Medical Dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life".

Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as pso.

Location: Coral 3

European biotechs often encounter difficulties in crafting narratives that capture investor interest as effectively as their US counterparts.

Opening questions:

· How can young CEOs cultivate storytelling skills that resonate with both European and global investors?

· How can young investors support biotechs to craft authentic narratives without losing scientific rigor?

Location: Coral 2

Explore the future of cell and gene therapy as industry experts tackle pressing questions and map the next wave of innovation. Discover the latest progress in the field whilst examining the current shortcomings and understanding the advancements still required to unlock the full potential of the therapeutic area.

Location: Coral 2

As neurological disorders continue to evolve, this session explores the cutting-edge innovations, transformative breakthroughs and latest deals in the field to address the complex challenges in neurology and uncover the strategic opportunities that lie ahead.

Location: Exhibit Hall Stage

As the biopharma services landscape continues to evolve, this session highlights the emerging trends, key challenges and innovative strategies for optimizing partnerships, and provides insights into improving efficiency and streamlining operations for service providers to thrive in a competitive market.

Location: Coral 1

Accelerated Biosciences is a regenerative medicine company with freedom-to-operate for the human Trophoblast Stem Cell (hTSC) platform, the earliest stem cells that can be sourced without ethical issues with over 117 granted and pending patents. We are providing GMP cells with a complete regulatory package to help cell and gene therapy developers accelerate their product time to market by 3 to 5 years with a potential of millions in savings. We have effectively de-risked the starting cell source decision for the regenerative medicine industry. We are available for partnering and licensing opportunities.

Location: Coral 1

AAVnerGene Inc. is an innovative biotech company developing new technologies to make AAV based gene therapy more accessible and affordable. It was founded in 2019 at Rockville, MD USA.
AAVnerGene addresses two major bottleneck problems: Manufacture and Delivery efficiency. The gene therapy drugs usually need very high dose, which leads to high side effects and high cost, seriously hindering research and drug development of AAV gene therapy. AAVnerGene developed AAVone to solve the manufacture problem, and ATHENA to solve the low delivery efficiency problem.
AAVone is a new one-plasmid AAV production system that has much higher production efficiency, ease to process and scale up, high quality, much lower cost and other advantages over the widely used triple plasmid transfection system. Application of AAVone for AAV production will solve the AAV manufacture problem, and make AAV gene therapy development easier, faster, effective and less costly.
AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening platform has high complexity to find the best AAV for each specific disease therapy, so to increase productivity, efficiency and specificity while decrease manufacture pressure, side effects, immunity and price. With tons of in house produced reliable data, we train our proprietary AI model to screen, analyze and rational-design efficient AAVs for next generation AAV gene therapy. We have engineered different AAVs for brain, lung, eye, heart, kidney and liver, and these AAVs can increase the delivery efficiency by hundreds of times.
These technologies are open to collaborate, licensing or sell.
Please refer to www.AAVnerGene.com for more information and send your questions to Daozhan.yu@aavnergene.com.

Location: Coral 1

Kolon Life Science (listed on KOSDAQ), a subsidiary of Kolon Group, is a South Korean biotech company established in 2000. One of its main business areas includes novel biopharmaceuticals, specializing in cell and gene therapies.

There are three gene therapy drug candidates: TG-C for osteoarthritis(US Ph 3 ongoing), KLS-2031 for neuropathic pain (US Ph 1/2a completed), and KLS-3021 as oncolytic virus.

We are currently seeking partners for business development, collaborative research and co-development of our drug assets.

Location: Coral 1

Basecamp Research is a biotech company that is bridging the data gap to make better predictions for protein and genome design using AI. Basecamp has built and legally owns a database of diverse sequences 900X larger than public databases combined that represent the Earth's diverse biomes to learn how nature creates biological molecules. We employ this platform to solve difficult biological problems not accessible to scientists without the use of large data and compute power. Basecamp is now using its proprietary database to solve programmable gene insertion , the next generation of gene writing tools for cell and gene therapies.

Location: Coral 1

Canopy is an emerging biotech redefining autoimmune therapeutics through its groundbreaking Antigen-Drug Conjugate (AgDC) platform. Backed by leading US-based VCs, the company is led by Dr. Kfir Oved, a serial bio-entrepreneur, alongside Chairman Cedric Francois (NASDAQ:APLS) and board member and investor John Cox (NASDAQ:DYNE).

AgDCs utilize two distinct MoAs to precisely target both autoreactive antibodies and pathological B-cell clones, sparing 99.9% of protective immunity. This innovative, non-immunosuppressive approach can potentially deliver long-term remission or even a cure, positioning AgDCs as potential first-line therapy for antibody-mediated autoimmune diseases.

Canopy is on track to initiate a Phase 1 trial for AChR+ MG in H1/26. Backed by robust IP including 14 patents across 8 patent families, the company's pipeline covers Graves' disease/Thyroid Eye Disease (TED), Pemphigus Vulgaris, Membranous Nephropathy, Immune Thrombocytopenic Purpura (ITP), and MuSK MG.

Location: Coral 1

As a trailblazer in the AIDD field, Insilico Medicine continues to innovate in developing AI tools for drug discovery and other science. We are expanding AI offerings in the generative biologics space, investing in robotics and AI combo, deepening our Chemistry42 offerings, and expanding AI efforts in sustainability. On the drug pipeline side, we have 20+ programs covering oncology, fibrosis, immunology and CNS, some of which are at Phase I or Phase II stage. We want to generate clinically meaningful data for the drug candidates that come from our AI-driven discovery programs and do more biopharma partnership deals.

Location: Coral 1

LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide.

Location: Coral 1

Location: Coral 1

Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patient.

Location: Coral 1

TargED Biopharmaceuticals B.V. is a Netherlands based biotechnology company developing first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using single-chain antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis. The company's lead compound, TGD001, is currently in development for the treatment of thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

Location: Coral 1

BiOMViS Srl, a Biotech Company located at the Toscana Life Sciences Scientific Park (Siena, IT), has developed a unique platform technology for the design of vaccines against infectious diseases and for cancer immunotherapy. The platform is based on Outer Membrane Vesicles (OMVs) released in the culture supernatant by proprietary non-pathogenic E. coli strains. Using patented synthetic Biology strategies, the OMVs can be decorated with virtually any antigen of bacterial and viral origin. Once purified using extremely simple and inexpensive procedure, the OMVs are ready-to-use vaccines, which do not require the addition of any other component before formulation. Thanks to their potent immunostimulatory activity, BiOMViS is also exploiting its OMVs in cancer immunotherapy both as personalized vaccines, once properly engineered with cancer neo-epitopes, and as vaccines broadly applicable in most solid tumors using in situ vaccination. BiOMViS has been exploiting its platform technology for the design of a variety of vaccines against important human pathogens, including: Staphylococcus aureus, Streptococcus pyogenes (Group A Streptococcus), Neisseria meningitidis Group B (MenB), Chlamydia, human Papilloma Virus, Coronavirus, Dengue Virus. Most of these vaccine candidates have completed the pre-clinical phase and are now ready to move to development. BiOMViS' business model is twofold. 1) the Company is seeking Pharma and Biotech Companies interested to test the BiOMViS' platform for their own vaccine pipeline and eventually to establish license agreements restricted to the specific vaccine of interest. 2) BiOMViS is willing to establish agreements with third Parties interested in developing some of the vaccines included in the list of BiOMViS' pipeline.

Location: Coral 1

KisoJi is a Canadian biotechnology company that deploys the latest scientific and AI tools to conduct therapeutic antibody discovery in a fundamentally new way.
KisoJi has developed a multi-species transgenic mouse to generate highly diverse single domain antibodies, as well as a modular multi-specific antibody scaffold with high stability and productivity. Most recently, KisoJi has used advanced AI tools to visualise the universe of all antibodies against a target in order to uncover novel biology and new therapeutic antibody capabilities for its partners and its own pipeline.